RedHill is advancing the management of gastrointestinal and infectious diseases with an extensive late-stage development pipeline of proprietary, oral, small-molecules with multiple near-term milestones, designed to help patients live extraordinary lives:

Drug Candidate Pre-Clinical Phase 1 Phase 2 Phase 3 NDA

Opaganib is a first-in-class new chemical entity with anti-inflammatory, anti-cancer and antiviral activity, under development for multiple indications. Opaganib is an orally administered, selective inhibitor of sphingosine kinase-2 (SPHK2), a lipid kinase with multiple cellular functions - potentially inhibiting tumor growth, pathological inflammation, and viral replication.

Read more
Acute Radiation Syndrome

Opaganib is being evaluated as a new therapeutic approach to mitigate gastrointestinal acute radiation syndrome (GI-ARS) in collaboration with the NIAID RNCP following the FDA Animal Rule regulatory pathway.

Read more
Global Phase 2/3 study

Opaganib’s unique mechanism of action combines potent antiviral and anti-inflammatory activities. Opaganib is host-targeted and is expected to remain effective against emerging viral variants.

Opaganib was studied in a global Phase 2/3 study in hospitalized patients with severe COVID-19 pneumonia (NCT04467840), achieving efficacy trends in key patient sub-groups despite not meeting the primary endpoint and previously delivered U.S. Phase 2 data in patients with moderate to severe COVID-19. RedHill is in ongoing discussions with multiple regulatory agencies regarding potential pathways to approval.

Read more
Phase 2 study

Opaganib has undergone a single-arm Phase 2a clinical study in patients with advanced, unresectable cholangiocarcinoma – an orphan indication with strong unmet medical need.

Prostate cancer
Phase 2 study

Opaganib has undergone an investigator-sponsored Phase 2 study evaluating its safety and efficacy in metastatic castration-resistant prostate cancer (mCRPC) that was progressing during treatment with androgen-signaling blockers abiraterone or enzalutamide.

Phase 2 study

RHB-107 (INN: upamostat) is a first-in-class, once-daily, orally-administered serine protease inhibitor targeting multiple indications, including viral infections such as COVID-19, oncology and gastrointestinal indications.

Read more
Phase 2 study

RHB-107 has been accepted for inclusion in the U.S. Government supported ACESO PROTECT study, an adaptive, randomized, double blind, multi-site Phase 2 platform trial for early COVID-19 outpatients which has received FDA clearance to start.

RHB-107 has already completed a U.S. Phase 2 study in non-hospitalized symptomatic COVID-19 patients which evaluated the safety and tolerability profile of RHB-107 and efficacy signals.

Read more

RHB-102 is a once-daily 24-hr bimodal release, oral tablet formulation of the antiemetic drug ondansetron, a 5-HT3 antagonist in development for oncology support and other gastrointestinal indications.

Read more
Oncology Support

RHB-102 (24 mg) is in development for the management of chemotherapy and radiotherapy induced nausea and vomiting (also referred to as CINV and RINV) in the UK.

Read more
Gastroenteritis and gastritis
Completed positive US Phase 3 study

RHB-102 (24 mg) successfully completed a randomized, double-blind, placebo-controlled U.S. Phase 3 study meeting the primary outcome measure, demonstrating its safety and efficacy in the treatment of acute gastroenteritis and gastritis.

Read more
Completed positive US Phase 2 study

RHB-102 (12 mg) successfully completed a positive randomized, double-blind, placebo-controlled U.S. Phase 2 study meeting the primary outcome measure, demonstrating its safety and efficacy in the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D).

Read more

RHB-204 is a Phase 3-stage fixed-dose oral capsule with potential as a first-line, stand-alone treatment of pulmonary nontuberculous mycobacteria (NTM) disease caused by Mycobacterium avium Complex (MAC).

Read more
NTM disease
Phase 3-stage

A Phase 3 study was recently terminated due to low a low accrual rate.


RHB-104 is an orally-administered, all-in-one combination antibiotic therapy, with intracellular, antimycobacterial and anti-inflammatory properties, in development for Crohn’s disease.

Read more
Crohn's disease
Completed positive Phase 3 study

RHB-104 has completed a positive first Phase 3 study in Crohn’s disease, meeting its primary and key secondary endpoints. It has also completed a positive Phase 2a proof-of-concept study in relapsing remitting multiple sclerosis.

* Estimated timeline/indication in the pipeline is subject to changes in development plans and regulatory requirements/ clarifications, including complementary /additional studies.

** The safety and efficacy of the agents for the indications under investigation have not been established.